NAMS Menopause Certification Exam
(MSCP) 200 Practice Questions with Verified
Answers & Rationales (Menopause Society
Certified Practitioner Test Bank)
Question 1
Does systemic ET cause fibroids to resume growth?
Correct Answer
Rarely. They often shrink after menopause.
Question 2
menstrual migraine after menopause
Correct Answer
should resolve completely
Question 3
Stress urinary incontinence
Correct Answer
Vaginal estrogen and urinary incontinence: what type does it help with?
Page 1 of 102
,Question 4
What ethnicity is the most likely to have bad hot flashes?
Correct Answer
black
more frequent, longer duration.
Question 1: What is the average age of natural menopause in women in the
United States?
A. 45 years
B. 51 years
C. 55 years
D. 60 years
CORRECT ANSWER: B. 51 years
Rationale: The average age of natural menopause in the United States is
approximately 51 years, with 95% of women experiencing it between ages 45 and
55. This is a key demographic fact in menopause physiology per NAMS guidelines.
Question 2: Which hormone therapy regimen is recommended for a woman
with an intact uterus experiencing menopausal symptoms?
A. Estrogen alone
B. Estrogen plus progestogen
C. Progestogen alone
D. Testosterone plus estrogen
CORRECT ANSWER: B. Estrogen plus progestogen
Rationale: In women with an intact uterus, estrogen plus progestogen is required to
protect the endometrium from hyperplasia and reduce the risk of endometrial
cancer associated with unopposed estrogen.
Question 3: What is the most effective treatment for moderate to severe
vasomotor symptoms such as hot flashes and night sweats?
A. Antidepressants like SSRIs
B. Systemic hormone therapy
C. Herbal supplements such as black cohosh
D. Acupuncture
CORRECT ANSWER: B. Systemic hormone therapy
Rationale: Systemic estrogen-containing hormone therapy is the most effective
treatment for vasomotor symptoms, reducing frequency and severity by up to 75-
Page 2 of 102
,80% in appropriate candidates.
Question 4: What is the primary risk factor for accelerated bone loss in
postmenopausal women?
A. High body mass index
B. Estrogen deficiency
C. Excessive calcium intake
D. Sedentary lifestyle alone
CORRECT ANSWER: B. Estrogen deficiency
Rationale: Estrogen deficiency following menopause accelerates bone resorption,
leading to decreased bone mineral density and increased osteoporosis risk.
Question 5: For a healthy woman under age 60 and within 10 years of
menopause onset without contraindications, how do the benefits of hormone
therapy for symptom management generally compare to risks?
A. Risks substantially outweigh benefits
B. Benefits generally outweigh risks
C. There are no benefits
D. Benefits equal risks in all cases
CORRECT ANSWER: B. Benefits generally outweigh risks
Rationale: For appropriately selected women, hormone therapy benefits for treating
vasomotor symptoms, improving quality of life, and preventing bone loss outweigh
risks according to current NAMS and FDA guidance.
Question 6: Which laboratory evaluations are recommended for a woman
under 40 years old experiencing amenorrhea for 3 or more consecutive cycles?
A. Glucose and FSH only
B. Prolactin, FSH, estradiol, TSH, and pregnancy test
C. Cortisol and testosterone
D. LH and progesterone only
CORRECT ANSWER: B. Prolactin, FSH, estradiol, TSH, and pregnancy test
Rationale: Comprehensive evaluation including these tests rules out prolactinoma,
thyroid dysfunction, pregnancy, and assesses for primary ovarian insufficiency in
young women with amenorrhea.
Question 7: What is the definition of primary ovarian insufficiency (POI)?
A. Menopause after age 55
B. Loss of ovarian function before age 40 with elevated FSH
Page 3 of 102
, C. Normal menopause at age 51
D. Temporary irregular cycles in perimenopause
CORRECT ANSWER: B. Loss of ovarian function before age 40 with elevated
FSH
Rationale: POI is characterized by amenorrhea, low estrogen, and elevated FSH
before age 40, requiring hormone therapy until average menopause age for
protection.
Question 8: Which route of estrogen administration in hormone therapy is
associated with lower risk of venous thromboembolism compared to oral?
A. Oral
B. Transdermal
C. Vaginal only
D. Intramuscular
CORRECT ANSWER: B. Transdermal
Rationale: Transdermal estradiol bypasses first-pass hepatic metabolism, resulting in
lower thrombotic risk than oral formulations.
Question 9: What is the STRAW+10 staging system primarily used for?
A. Classifying breast cancer stages
B. Standardizing menopause transition stages
C. Assessing cardiovascular risk
D. Measuring bone density
CORRECT ANSWER: B. Standardizing menopause transition stages
Rationale: The STRAW+10 system provides a standardized framework for describing
stages of reproductive aging including menopausal transition.
Question 10: For genitourinary syndrome of menopause (GSM), what is the
preferred initial treatment for vaginal symptoms?
A. Systemic hormone therapy only
B. Low-dose local vaginal estrogen
C. Oral antidepressants
D. Pelvic floor surgery
CORRECT ANSWER: B. Low-dose local vaginal estrogen
Rationale: Local vaginal estrogen is highly effective for GSM symptoms like dryness
and dyspareunia with minimal systemic absorption.
Page 4 of 102
(MSCP) 200 Practice Questions with Verified
Answers & Rationales (Menopause Society
Certified Practitioner Test Bank)
Question 1
Does systemic ET cause fibroids to resume growth?
Correct Answer
Rarely. They often shrink after menopause.
Question 2
menstrual migraine after menopause
Correct Answer
should resolve completely
Question 3
Stress urinary incontinence
Correct Answer
Vaginal estrogen and urinary incontinence: what type does it help with?
Page 1 of 102
,Question 4
What ethnicity is the most likely to have bad hot flashes?
Correct Answer
black
more frequent, longer duration.
Question 1: What is the average age of natural menopause in women in the
United States?
A. 45 years
B. 51 years
C. 55 years
D. 60 years
CORRECT ANSWER: B. 51 years
Rationale: The average age of natural menopause in the United States is
approximately 51 years, with 95% of women experiencing it between ages 45 and
55. This is a key demographic fact in menopause physiology per NAMS guidelines.
Question 2: Which hormone therapy regimen is recommended for a woman
with an intact uterus experiencing menopausal symptoms?
A. Estrogen alone
B. Estrogen plus progestogen
C. Progestogen alone
D. Testosterone plus estrogen
CORRECT ANSWER: B. Estrogen plus progestogen
Rationale: In women with an intact uterus, estrogen plus progestogen is required to
protect the endometrium from hyperplasia and reduce the risk of endometrial
cancer associated with unopposed estrogen.
Question 3: What is the most effective treatment for moderate to severe
vasomotor symptoms such as hot flashes and night sweats?
A. Antidepressants like SSRIs
B. Systemic hormone therapy
C. Herbal supplements such as black cohosh
D. Acupuncture
CORRECT ANSWER: B. Systemic hormone therapy
Rationale: Systemic estrogen-containing hormone therapy is the most effective
treatment for vasomotor symptoms, reducing frequency and severity by up to 75-
Page 2 of 102
,80% in appropriate candidates.
Question 4: What is the primary risk factor for accelerated bone loss in
postmenopausal women?
A. High body mass index
B. Estrogen deficiency
C. Excessive calcium intake
D. Sedentary lifestyle alone
CORRECT ANSWER: B. Estrogen deficiency
Rationale: Estrogen deficiency following menopause accelerates bone resorption,
leading to decreased bone mineral density and increased osteoporosis risk.
Question 5: For a healthy woman under age 60 and within 10 years of
menopause onset without contraindications, how do the benefits of hormone
therapy for symptom management generally compare to risks?
A. Risks substantially outweigh benefits
B. Benefits generally outweigh risks
C. There are no benefits
D. Benefits equal risks in all cases
CORRECT ANSWER: B. Benefits generally outweigh risks
Rationale: For appropriately selected women, hormone therapy benefits for treating
vasomotor symptoms, improving quality of life, and preventing bone loss outweigh
risks according to current NAMS and FDA guidance.
Question 6: Which laboratory evaluations are recommended for a woman
under 40 years old experiencing amenorrhea for 3 or more consecutive cycles?
A. Glucose and FSH only
B. Prolactin, FSH, estradiol, TSH, and pregnancy test
C. Cortisol and testosterone
D. LH and progesterone only
CORRECT ANSWER: B. Prolactin, FSH, estradiol, TSH, and pregnancy test
Rationale: Comprehensive evaluation including these tests rules out prolactinoma,
thyroid dysfunction, pregnancy, and assesses for primary ovarian insufficiency in
young women with amenorrhea.
Question 7: What is the definition of primary ovarian insufficiency (POI)?
A. Menopause after age 55
B. Loss of ovarian function before age 40 with elevated FSH
Page 3 of 102
, C. Normal menopause at age 51
D. Temporary irregular cycles in perimenopause
CORRECT ANSWER: B. Loss of ovarian function before age 40 with elevated
FSH
Rationale: POI is characterized by amenorrhea, low estrogen, and elevated FSH
before age 40, requiring hormone therapy until average menopause age for
protection.
Question 8: Which route of estrogen administration in hormone therapy is
associated with lower risk of venous thromboembolism compared to oral?
A. Oral
B. Transdermal
C. Vaginal only
D. Intramuscular
CORRECT ANSWER: B. Transdermal
Rationale: Transdermal estradiol bypasses first-pass hepatic metabolism, resulting in
lower thrombotic risk than oral formulations.
Question 9: What is the STRAW+10 staging system primarily used for?
A. Classifying breast cancer stages
B. Standardizing menopause transition stages
C. Assessing cardiovascular risk
D. Measuring bone density
CORRECT ANSWER: B. Standardizing menopause transition stages
Rationale: The STRAW+10 system provides a standardized framework for describing
stages of reproductive aging including menopausal transition.
Question 10: For genitourinary syndrome of menopause (GSM), what is the
preferred initial treatment for vaginal symptoms?
A. Systemic hormone therapy only
B. Low-dose local vaginal estrogen
C. Oral antidepressants
D. Pelvic floor surgery
CORRECT ANSWER: B. Low-dose local vaginal estrogen
Rationale: Local vaginal estrogen is highly effective for GSM symptoms like dryness
and dyspareunia with minimal systemic absorption.
Page 4 of 102
